Samuel Campanelli Freitas Couto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Samuel Campanelli Freitas Couto has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
Alfredo Mendrone Junior
Fundação Pró-Sangue-Hemocentro de São Paulo, São Paulo, Brazil
1 shared publicationAndres Caicedo
Universidad San Francisco de Quito Colegio de Ciencias de la Salud; Mito-Act Research Consortium, Quito, Ecuador; Universidad San Francisco de Quito, Instituto de Investigaciones en biomedicina iBiomed, Quito; Universidad San Francisco de Quito Space Front, Quito
1 shared publicationAndreza Feitoza
Hospital Israelita Albert Einstein, São Paulo, SP, Brazil
1 shared publication- Beatriz Brunini
Center for Cell-based Therapy (CTC), Regional Blood Center of Ribeirão Preto, University of São Paulo, Ribeirão Preto, São Paulo, Brazil
1 shared publication Dante Mário Langhi Junior
Escola Paulista de Medicina, Universidade Federal de São Paulo (EPM UNIFESP), São Paulo, SP, Brazil
1 shared publicationDimas Tadeu Covas
Hemocentro de Ribeirão Preto, Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo (HCFMRP-USP), Ribeirão Preto, SP, Brazil; Instituto Butantan, São Paulo, SP, Brazil
1 shared publication
Latest Publications
- Open Access
- 7 March 2026
- Published by Elsevier in Cytotherapy
- Vol. 28 (9) , 102142
South America and Mexico’s Cell and Gene Therapy Landscape: Accelerating Growth and Persistent Challenges
- 7 March 2026
- Published by Elsevier in Cytotherapy
- Vol. 28 (9) , 102142
Open AccessSouth America and Mexico’s Cell and Gene Therapy Landscape: Accelerating Growth and Persistent Challenges
- Open Access
- 10 December 2021
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 9, 784421
Myeloid Immune Cells CARrying a New Weapon Against Cancer
Chimeric antigen receptor (CAR) engineering for T cells and natural killer cells (NK) are now under clinical evaluation for the treatment of hematologic cancers. Although encouraging clinical results have been reported for hematologic diseases, pre-clinical studies in solid tumors have failed to prove the same effectiveness. Thus, there is a growing interest of the scientific community to find other immune cell candidate to express CAR for the treatment of solid tumors and other diseases. Mononuclear phagocytes may be the most adapted group of cells with potential to overcome the dense barrier imposed by solid tumors. In addition, intrinsic features of these cells, such as migration, phagocytic capability, release of soluble factors and adaptive immunity activation, could be further explored along with gene therapy approaches. Here, we discuss the elements that constitute the tumor microenvironment, the features and advantages of these cell subtypes and the latest studies using CAR-myeloid immune cells in solid tumor models.
- 10 December 2021
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 9, 784421
Open AccessMyeloid Immune Cells CARrying a New Weapon Against Cancer
Chimeric antigen receptor (CAR) engineering for T cells and natural killer cells (NK) are now under clinical evaluation for the treatment of hematologic cancers. Although encouraging clinical results have been reported for hematologic diseases, pre-clinical studies in solid tumors have failed to prove the same effectiveness. Thus, there is a growing interest of the scientific community to find other immune cell candidate to express CAR for the treatment of solid tumors and other diseases. Mononuclear phagocytes may be the most adapted group of cells with potential to overcome the dense barrier imposed by solid tumors. In addition, intrinsic features of these cells, such as migration, phagocytic capability, release of soluble factors and adaptive immunity activation, could be further explored along with gene therapy approaches. Here, we discuss the elements that constitute the tumor microenvironment, the features and advantages of these cell subtypes and the latest studies using CAR-myeloid immune cells in solid tumor models.
- Open Access
- 16 November 2021
- Published by Elsevier in Hematology, Transfusion and Cell Therapy
- Vol. 43 (Suppl 2) , S35-S41
Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. V: Manufacture and quality control
- 16 November 2021
- Published by Elsevier in Hematology, Transfusion and Cell Therapy
- Vol. 43 (Suppl 2) , S35-S41
Open AccessAssociação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. V: Manufacture and quality control